Enzon Pharmaceuticals, Inc. (ENZN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cranford, NJ, アメリカ. 現CEOは Richard L. Feinstein.
ENZN を有する IPO日 1984-02-15, に上場 Other OTC, 時価総額 $4.45M.
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
